LARGE B-CELL LYMPHOMA (LBCL)
Clinical trials for LARGE B-CELL LYMPHOMA (LBCL) explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA (LBCL) trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage trial is testing a new combination of three drugs—golcadomide, poseltinib, and rituximab—for adults with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to prior treatment. The main goal is …
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug aims to boost Cancer-Killing power of CAR-T therapy
Disease control Not yet recruitingThis early-stage study is testing the safety of adding an experimental drug called CLS-015 to standard CAR-T cell therapy for adults with large B-cell lymphoma. It focuses on patients whose cancer is stable or growing just before their CAR-T treatment, a group with a high risk of…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New immune cell therapy tested for tough blood cancers
Disease control Not yet recruitingThis early-stage study is testing a new type of CAR-T cell therapy for adults with large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see if it helps shrink tumors. Only three participants …
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC